KVK Tech, Inc. Launches First Mobile App
The Daily Dose Tracker will alert patients when to take their medicine
NEWTOWN, Pa., Dec. 12, 2017 /PRNewswire/ -- KVK Tech, Inc., the manufacturer and marketer of LOMAIRA™ (phentermine hydrochloride USP) 8 mg tablets, CIV, today announced the launch of its first mobile app, the LOMAIRA Daily Dose Tracker, available for Android and iOS.
Medications don't work if they're not taken. It is estimated that three out of four Americans do not take their medication as prescribed by the healthcare provider.1 One reason for non-adherence is that patients simply forget to take the medication.
The LOMAIRA Daily Dose Tracker app allows patients to enter a unique schedule as prescribed by their healthcare provider for daily dosing of LOMAIRA. In addition, the free app tracks a patient's weight-reduction progress, provides refill reminders, and a visual history of LOMAIRA dosing and dosing adjustments indicated by the healthcare provider to meet each patient's unique lifestyle and eating patterns.
"Even though hunger near or at mealtime can be an auto-alert for medication administration, our thought leaders and patient influencers express that daily reminders would be helpful to ensure that the opportunity to suppress appetite isn't missed," states Anthony Tabasso, President and CEO at KVK. "We are happy to help patients improve medication adherence."
About LOMAIRA
LOMAIRA is a low dose of the #1 prescribed medicine for weight loss in the United States, phentermine HCl. Unlike the higher strengths of phentermine that are dosed in the morning before or shortly after breakfast, LOMAIRA is FDA-approved to be used up to three times a day before meals. The usual adult dose is one tablet 30 mins before each meal. Late night medication should be avoided.
INDICATION
LOMAIRA™ (phentermine hydrochloride USP) 8 mg tablets, CIV is a prescription medicine used for a short period of time (a few weeks) for weight reduction and should be used together with regular exercise and a reduced-calorie diet. LOMAIRA is for adults with an initial BMI* of 30 or more (obese) or 27 or more (overweight) with at least one weight-related medical condition such as controlled high blood pressure, diabetes, or high cholesterol. The limited usefulness of this drug class (anorectics), including LOMAIRA, should be measured against possible risk factors inherent in their use.
IMPORTANT SAFETY INFORMATION
Don't take LOMAIRA if you have a history of cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure or uncontrolled high blood pressure); are taking or have taken a monoamine oxidase inhibitor drug (MAOI) within the past 14 days; have overactive thyroid, glaucoma (increased pressure in the eyes), agitation or a history of drug abuse; are pregnant, nursing, or allergic to the sympathomimetic amines such as phentermine or any of the ingredients in LOMAIRA.
Taking phentermine with other drugs for weight loss is not recommended. Primary pulmonary hypertension (PPH), a rare fatal lung disease, has been reported in patients who had taken a combination of phentermine and fenfluramine or dexfenfluramine for weight loss. The possible association between phentermine use alone and PPH cannot be ruled out. Patients should report immediately if they experience any decrease in the amount of exercise that they can normally tolerate, shortness of breath, chest or heart pain, fainting or swelling in the lower legs.
Serious heart valve problems or disease have been reported in patients taking a combination of phentermine and fenfluramine or dexfenfluramine for weight loss. The possible role of phentermine has not been established, therefore the possibility of an association between heart valve disease and the use of phentermine alone cannot be ruled out.
If your body becomes adjusted to the maximum dose of phentermine so that its effects are experienced less strongly, the maximum dose should not be exceeded in an attempt to increase the effect.
Caution is advised when engaging in potentially hazardous activity such as driving or operating machinery while taking phentermine. Phentermine has the potential to be abused. Keep LOMAIRA in a safe place to prevent theft, accidental overdose, misuse or abuse. Using alcohol with phentermine may result in an adverse drug reaction.
Phentermine can cause an increase in blood pressure. Tell your doctor if you have high blood pressure, even if it's mild. If you are taking medicines for type 2 diabetes, your doctor may have to adjust these medicines while taking phentermine.
Some side effects of phentermine that have been reported include pulmonary hypertension, valvular heart disease, palpitations, increased heart rate or blood pressure, insomnia, restlessness, dry mouth, diarrhea, constipation and changes in sexual drive. These are not all of the potential side effects of phentermine. For more information, ask your doctor or pharmacist.
To report negative side effects of prescription drugs, contact FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch.
See accompanying Full Prescribing Information at www.lomaira.com.
About KVK Tech
KVK is a leader in the development and manufacture of high-quality, FDA-approved medicines that address unmet patient needs. Founded in 2004, KVK takes pride in its ability to advance medical care and offer low-cost alternatives in response to today's healthcare challenges. All of KVK's products are made in the U.S.A. in a state-of-the-art facility in Newtown, PA. KVK is committed to maintaining its entire business operations in America, as it continues to build strong, lasting relationships with the nation's largest pharmacy chains, wholesalers and distributors.
*Body Mass Index (BMI) measures the amount of fat in the body based on height and weight. BMI is measured in kg/m2.
SOURCE KVK Tech, Inc.
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article